See more : Mishka Exim Limited (MISHKA.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Protara Therapeutics, Inc. (TARA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Protara Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Canadian Utilities Limited 2ND PFD SER DD% (CNUTF) Income Statement Analysis – Financial Results
- Sarytogan Graphite Limited (SGA.AX) Income Statement Analysis – Financial Results
- Blue Jet Healthcare Limited (BLUEJET.NS) Income Statement Analysis – Financial Results
- Electronic Sensor Technology, Inc. (ESNR) Income Statement Analysis – Financial Results
- PT Paninvest Tbk (PNIN.JK) Income Statement Analysis – Financial Results
Protara Therapeutics, Inc. (TARA)
About Protara Therapeutics, Inc.
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.95M | 0.00 | 0.00 |
| Cost of Revenue | 341.00K | 247.00K | 1.17M | 196.00K | 16.00K | 115.00K | 148.00K | 123.00K | 57.00K | 0.00 | 27.00K | 57.00K |
| Gross Profit | -341.00K | -247.00K | -1.17M | -196.00K | -16.00K | -115.00K | -148.00K | -123.00K | -57.00K | 2.95M | -27.00K | -57.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 24.99M | 16.81M | 21.09M | 11.98M | 6.44M | 15.51M | 21.69M | 18.87M | 12.38M | 6.43M | 3.99M | 5.91M |
| General & Administrative | 18.62M | 20.74M | 26.40M | 22.46M | 8.82M | 10.57M | 105.99K | 9.84M | 8.49M | 4.10M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.42M | -123.00K | -57.00K | 0.00 | 0.00 | 0.00 |
| SG&A | 18.62M | 20.74M | 26.40M | 22.46M | 8.82M | 10.57M | 8.53M | 9.71M | 8.43M | 4.10M | 3.10M | 2.03M |
| Other Expenses | 0.00 | 29.52M | 0.00 | 0.00 | 0.00 | 207.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 43.61M | 37.55M | 47.49M | 34.44M | 15.25M | 26.08M | 30.21M | 28.58M | 20.81M | 10.53M | 7.10M | 7.94M |
| Cost & Expenses | 43.61M | 37.55M | 47.49M | 34.44M | 15.25M | 26.08M | 30.36M | 28.71M | 20.87M | 10.53M | 7.12M | 8.00M |
| Interest Income | 2.73M | 1.11M | 237.00K | 466.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.00K | 20.00K |
| Interest Expense | 0.00 | 1.14M | 1.74M | 34.00K | 0.00 | 0.00 | 259.00K | 193.00K | 144.00K | 857.00K | 861.00K | 0.00 |
| Depreciation & Amortization | 341.00K | 247.00K | 1.17M | 196.00K | 16.00K | 115.00K | 148.00K | 123.00K | 57.00K | 30.00K | 27.00K | 57.00K |
| EBITDA | -43.27M | -64.57M | -46.09M | -33.78M | -7.81M | -20.61M | -29.82M | -28.40M | -21.32M | -2.45M | -7.02M | -7.91M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -83.28% | 0.00% | 0.00% |
| Operating Income | -43.61M | -67.06M | -47.49M | -34.44M | -15.25M | -26.08M | -30.36M | -28.71M | -20.87M | -7.58M | -7.12M | -8.00M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -257.12% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.19M | 1.11M | 237.00K | 466.00K | 0.00 | 643.00K | 398.00K | 179.00K | -507.00K | 4.24M | -790.00K | 26.00K |
| Income Before Tax | -40.42M | -65.95M | -47.25M | -33.98M | -14.99M | -25.44M | -29.96M | -28.53M | -21.38M | -3.34M | -7.91M | -7.97M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -113.36% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.14M | -117.00K | -466.00K | -262.00K | 5.35M | 657.00K | 372.00K | -363.00K | 5.10M | 0.00 | 0.00 |
| Net Income | -40.42M | -64.82M | -47.14M | -33.51M | -14.73M | -25.44M | -29.96M | -28.53M | -21.38M | -3.34M | -7.91M | -7.97M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -113.36% | 0.00% | 0.00% |
| EPS | -3.57 | -5.76 | -4.20 | -4.63 | -228.60 | -9.93 | -69.38 | -68.90 | -51.94 | -43.62 | -37.43 | -37.62 |
| EPS Diluted | -3.57 | -5.76 | -4.20 | -4.63 | -228.60 | -9.93 | -69.38 | -68.90 | -51.94 | -43.62 | -37.43 | -37.62 |
| Weighted Avg Shares Out | 11.33M | 11.26M | 11.23M | 7.23M | 64.44K | 2.56M | 431.86K | 414.04K | 411.60K | 76.61K | 374.85K | 374.85K |
| Weighted Avg Shares Out (Dil) | 11.33M | 11.26M | 11.23M | 7.23M | 64.44K | 2.56M | 431.86K | 414.04K | 411.60K | 76.61K | 374.85K | 374.85K |
TARA Stock Soars on Superior Efficacy of Bladder Cancer Cell Therapy
Protara stock surges 70% as investigational cell therapy, TARA-002, shows superior six-month efficacy in phase II bladder cancer study.
Why Is Protara Therapeutics Stock Skyrocketing Over 100% On Thursday?
On Thursday, Protara Therapeutics Inc. TARA stock traded higher after the company revealed results from its ongoing Phase 2 open-label ADVANCED-2 trial.
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology
NEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that data from an interim analysis of the ongoing Phase 2 open-label ADVANCED-2...
Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference
NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a fireside chat at the Guggenheim Inaugural Healthcare...
Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support
NEW YORK, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast...
Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced completion of the first cohort of the Phase 2 STARBORN-1 trial...
Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support
NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the results of THRIVE-1, a prospective, observational study evaluating the prevalence...
Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the H.C. Wainwright 26th Annual Global Investment Conference...
Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the grant of inducement non-qualified stock options to purchase an...
Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit
NEW YORK, May 21, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a virtual fireside chat at the TD Cowen...
Source: https://incomestatements.info
Category: Stock Reports